📣 VC round data is live. Check it out!

ChemoMetec Valuation Multiples

Discover revenue and EBITDA valuation multiples for ChemoMetec and similar public comparables like Barco, InMode, MedCap, Dynavox Group and more.

ChemoMetec Overview

About ChemoMetec

ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.


Founded

1997

HQ

Denmark

Employees

170

Financials (LTM)

Revenue: $80M
EBITDA: $43M

EV

$809M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

ChemoMetec Financials

ChemoMetec reported last 12-month revenue of $80M and EBITDA of $43M.

In the same LTM period, ChemoMetec generated $68M in gross profit, $43M in EBITDA, and $31M in net income.

Revenue (LTM)


ChemoMetec P&L

In the most recent fiscal year, ChemoMetec reported revenue of $78M and EBITDA of $41M.

ChemoMetec is profitable as of last fiscal year, with gross margin of 93%, EBITDA margin of 53%, and net margin of 38%.

See analyst estimates for ChemoMetec
LTMLast FY202320242025202620272028
Revenue$80M$78M$67M$71M$79M
Gross Profit$68M$73M$60M$65M$70M
Gross Margin85%93%90%92%89%
EBITDA$43M$41M$35M$36M$42M
EBITDA Margin55%53%52%50%54%
EBIT Margin49%47%47%45%49%
Net Profit$31M$29M$25M$25M$30M
Net Margin39%38%37%36%38%

Financial data powered by Morningstar, Inc.

ChemoMetec Stock Performance

ChemoMetec has current market cap of $851M, and enterprise value of $809M.

Market Cap Evolution


ChemoMetec's stock price is $48.91.

ChemoMetec share price decreased by 2.2% in the last 30 days, and by 40.0% in the last year.

ChemoMetec has an EPS (earnings per share) of $1.68.

See more trading valuation data for ChemoMetec
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$809M$851M-0.5%-2.2%-26.4%-40.0%$1.68

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

ChemoMetec Valuation Multiples

ChemoMetec trades at 10.1x EV/Revenue multiple, and 18.6x EV/EBITDA.

See NTM and 2027E valuation multiples for ChemoMetec

EV / Revenue (LTM)


ChemoMetec Financial Valuation Multiples

As of May 16, 2026, ChemoMetec has market cap of $851M and EV of $809M.

ChemoMetec has a P/E ratio of 27.7x.

LTMLast FY202320242025202620272028
EV/Revenue10.1x10.4x12.2x11.5x10.3x
EV/EBITDA18.6x19.8x23.3x22.7x19.1x
EV/EBIT20.7x21.9x25.9x25.6x21.2x
EV/Gross Profit12.0x11.1x13.6x12.4x11.5x
P/E27.7x29.1x34.6x33.8x28.3x
EV/FCF37.8x36.3x52.2x45.4x37.1x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified ChemoMetec Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

ChemoMetec Margins & Growth Rates

ChemoMetec grew revenue by 3% and EBITDA by 7% in the last fiscal year.

In the most recent fiscal year, ChemoMetec reported gross margin of 93%, EBITDA margin of 53%, and net margin of 38%.

See estimated margins and future growth rates for ChemoMetec

ChemoMetec Margins

Last FY202420252026202720282029
Gross Margin93%92%89%85%
EBITDA Margin53%50%54%55%
EBIT Margin47%45%49%49%
Net Margin38%36%38%39%
FCF Margin29%25%28%29%

ChemoMetec Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth3%6%12%7%
Gross Profit Growth(6%)9%8%2%
EBITDA Growth7%2%19%8%
EBIT Growth7%1%21%8%
Net Profit Growth6%2%19%9%
FCF Growth(4%)15%23%11%

Data powered by FactSet, Inc. and Morningstar, Inc.

ChemoMetec Operational KPIs

ChemoMetec's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.

ChemoMetec's Rule of 40 is 61% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

ChemoMetec's Rule of X is 71% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for ChemoMetec
LTMLast FY202320242025202620272028
Rule of 4063%61%
Bessemer Rule of X77%71%
Revenue per Employee$0.5M
Opex per Employee$0.2M
Opex to Revenue46%43%47%45%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

ChemoMetec Competitors

ChemoMetec competitors include Barco, InMode, MedCap, Dynavox Group, Tandem Diabetes Care, Alpha Tau Medical, SS Innovations, PHC Holdings, SEEGENE and Nanosonics.

Most ChemoMetec public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Barco0.6x0.6x4.2x4.3x
InMode0.8x0.8x3.2x3.5x
MedCap3.7x3.7x17.2x16.6x
Dynavox Group3.5x3.4x15.4x14.6x
Tandem Diabetes Care1.0x1.0x(22.6x)(126.1x)
Alpha Tau Medical1793.3x(20.8x)(19.0x)
SS Innovations18.2x(129.2x)
PHC Holdings0.9x0.9x6.1x6.1x

This data is available for Pro users. Sign up to see all ChemoMetec competitors and their valuation data.

Start Free Trial

ChemoMetec M&A Activity

ChemoMetec has acquired 1 company to date.

Last acquisition by ChemoMetec was on October 22nd 2024. ChemoMetec acquired Ovizio for $3M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by ChemoMetec

Ovizio
Description
Ovizio is a Brussels-based developer of digital holographic microscopy systems for real-time 4D imaging of live cells. Its Imagio platform combines interferometry with quantitative phase imaging to track cell movement, division, and morphology without labels in perfusion bioreactors. Targeted at biopharma R&D, the technology supports process analytical tools for stem cell therapy and vaccine production monitoring.
HQ CountryBelgium
HQ City
Brussels
Deal Date22 Oct 2024
Valuation$3M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all ChemoMetec acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About ChemoMetec

When was ChemoMetec founded?ChemoMetec was founded in 1997.
Where is ChemoMetec headquartered?ChemoMetec is headquartered in Denmark.
How many employees does ChemoMetec have?As of today, ChemoMetec has over 170 employees.
Is ChemoMetec publicly listed?Yes, ChemoMetec is a public company listed on Nasdaq Copenhagen.
What is the stock symbol of ChemoMetec?ChemoMetec trades under CHEMM ticker.
When did ChemoMetec go public?ChemoMetec went public in 2006.
Who are competitors of ChemoMetec?ChemoMetec main competitors include Barco, InMode, MedCap, Dynavox Group, Tandem Diabetes Care, Alpha Tau Medical, SS Innovations, PHC Holdings, SEEGENE, Nanosonics.
What is the current market cap of ChemoMetec?ChemoMetec's current market cap is $851M.
What is the current revenue of ChemoMetec?ChemoMetec's last 12 months revenue is $80M.
What is the current revenue growth of ChemoMetec?ChemoMetec revenue growth (NTM/LTM) is 9%.
What is the current EV/Revenue multiple of ChemoMetec?Current revenue multiple of ChemoMetec is 10.1x.
Is ChemoMetec profitable?Yes, ChemoMetec is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of ChemoMetec?ChemoMetec's last 12 months EBITDA is $43M.
What is ChemoMetec's EBITDA margin?ChemoMetec's last 12 months EBITDA margin is 55%.
What is the current EV/EBITDA multiple of ChemoMetec?Current EBITDA multiple of ChemoMetec is 18.6x.
What is the current FCF of ChemoMetec?ChemoMetec's last 12 months FCF is $21M.
What is ChemoMetec's FCF margin?ChemoMetec's last 12 months FCF margin is 27%.
What is the current EV/FCF multiple of ChemoMetec?Current FCF multiple of ChemoMetec is 37.8x.
How many companies ChemoMetec has acquired to date?As of May 2026, ChemoMetec has acquired 1 company.
What was the largest acquisition by ChemoMetec?$3M acquisition of Ovizio on 22nd October 2024 was the largest M&A ChemoMetec has done to date.
What companies ChemoMetec acquired?ChemoMetec acquired Ovizio.
In how many companies ChemoMetec has invested to date?ChemoMetec hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to ChemoMetec

Lists including ChemoMetec

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial